- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00774943
A Study of AMG 557 in Adults With Systemic Lupus Erythematosus
April 5, 2013 updated by: Amgen
A Randomized, Double-blind, Placebo-controlled, Ascending, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 557 in Subjects With Systemic Lupus Erythematosus
This is a Phase 1, randomized, placebo-controlled, double-blind, dose-escalation study of repeat SC doses of AMG 557 in adults with Systemic Lupus Erythematosus.
Study Overview
Study Type
Interventional
Enrollment (Actual)
58
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
Newmarket, Ontario, Canada, L3Y 3R7
- Research Site
-
-
-
-
Alabama
-
Anniston, Alabama, United States, 36207
- Research Site
-
-
Arizona
-
Phoenix, Arizona, United States, 85013
- Research Site
-
-
California
-
San Leandro, California, United States, 94578
- Research Site
-
-
Connecticut
-
Danbury, Connecticut, United States, 06810
- Research Site
-
-
Florida
-
Miami, Florida, United States, 33143
- Research Site
-
-
Indiana
-
Michigan City, Indiana, United States, 46360
- Research Site
-
-
New York
-
Manhasset, New York, United States, 11030
- Research Site
-
Rochester, New York, United States, 14642
- Research Site
-
-
Pennsylvania
-
Duncansville, Pennsylvania, United States, 16635
- Research Site
-
-
Texas
-
Amarillo, Texas, United States, 79124
- Research Site
-
Dallas, Texas, United States, 75231
- Research Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Before any study-specific procedure, the appropriate written informed consent must be obtained;
- Men and women, between the ages of 18 and 70 years old, inclusive, at the time of randomization;
- Diagnosis of SLE as defined by the most recent ACR criteria, including a positive ANA at screening or documented positive ANA (the titer should be at least 1:80) in the past.
- SLE duration of at least six months, as diagnosed by a physician;
- Stable disease, defined as no change in SLE therapy within the previous 30 days; and, in the opinion of the investigator, no anticipated need for a change in SLE therapy will be required while the subject is enrolled in the study;
- Normal or clinically acceptable ECG (12-lead reporting ventricular rate and PR, QRS, QT, QTc) at screening and Day -1 based on the opinion of the investigator;
- Body mass index from 18 to 40 kg/m2 at screening;
- Able and willing to complete entire study according to study schedule.
- Immunizations up to date, with a minimum of tetanus, diphtheria, pertussis (td/Tdap), pneumococcal (polysaccharide) and influenza (during flu season) vaccinations, as determined by the Principal Investigator.
Exclusion Criteria:
- Positive serology for HIV antibodies, hepatitis B surface antigen or hepatitis C antibodies (confirmed by PCR or RIBA);
- Have had signs or symptoms of a viral, bacterial or fungal infection within 30 days of study randomization;
- Evidence of active or latent tuberculosis as assessed by PPD or Quantiferon testing at screening;
- Have donated blood or experienced a loss of blood >500mL within 4 weeks of randomization;
- History of ethanol or drug abuse within the last one year prior to randomization;
- Evidence of significant renal insufficiency, defined by:
The glomerular fitration rate < 50 mL/min using the Cockroft and Gault equation;
- Evidence of liver disease (eg, serum ALT or AST > 2x upper limit of normal);
- Total WBC <3000 x 106/L;
- Neutrophil count < 1500 x106/L
- Platelet count <75,000 x 106/L
- Hemoglobin <10g/dL
- Any disorder (including psychiatric), condition or clinically significant disease (other than a diagnosis of SLE) that would, by it progressive nature and/or severity, interfere with the study evaluation, completion and/or procedures in the medical judgment of the investigator. This includes any age related co-morbidites such as presence of congestive heart failure, angina, chronic obstructive pulmonary disease, asthma, and malignancies (other than resected squamous and basal cell carcinoma of the skin).
- Presence or history of vasculitis (comprising internal organs or extremities or leading to peripheral neuropathy) within the last 3 years, presence or history of active CNS lupus (defined as seizure disorder, cerebral vascular accident, psychosis ascribed to SLE , encephalitis, meningitis, and myelitis) requiring therapy within the last 3 years;
- Uncontrolled hypertension (Blood pressure > 150/95);
- Poorly controlled diabetes (HbA1c > 8%);
- Any history of granulomatous disease including autoimmune granulomatous vasculitis and sarcoidosis;
- Underlying condition that predisposes the subject to infections (eg, history of splenectomy);
- Any disorder or condition that prevents the subject from providing truly informed consent;
- Prior administration of any other biologic that primarily targets the immune system (eg, Lymphostat-B, TACI-Ig, or CTLA4-Ig) in the past 9 months. This includes prior administration of AMG 557;
- Presence of AMG 557 anti-bodies;
- Prior administration of rituximab > 9 months with CD19+ B cells <5/µL;
- Administration of cyclophosphamide (or any other alkylating agent), cyclosporine, tacrolimus, or sirolimus, or > 100 mg/day prednisone or equivalent in the 6 months prior to randomization;
- Participated in an investigational drug trial involving a monoclonal antibody (not targeting the immune system) within 3 months or 5 half-lives, whichever time period is longer, prior to randomization;
- Participated in any another investigational drug or device trial within the previous 30 days or 5 half-lives, whichever time period is longer, prior to randomization;
- Administration of >10 mg/day prednisone (or equivalent) in the 30 days prior to randomization;
- Known sensitivity to mammalian derived products;
- Unwilling to practice an effective method of double-barrier contraception as determined by the investigator for the duration of the study;
- Positive serum hCG at screening or positive urine hCG on D-1; or females who are currently lactating;
- Known allergies to shellfish or any excipients found in KLH;
- Previous immunization with KLH.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: FACTORIAL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
PLACEBO_COMPARATOR: Placebo
|
A total of 4 cohorts will be administered multiple doses of drug or placebo subcutaneously.
Dose escalation will take place by cohort.
|
ACTIVE_COMPARATOR: AMG 557
|
A total of 4 cohorts will be administered multiple doses of drug or placebo subcutaneously.
Dose escalation will take place by cohort.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Subject incidence of treatment-emergent adverse events and the incidence of antibodies to AMG 557.
Time Frame: Throughout study period
|
Throughout study period
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Serum PK profile of AMG 557 after multiple dose administrations. Biomarkers of pharmacodynamic activity for AMG 557.
Time Frame: Throughout study period
|
Throughout study period
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Sullivan BA, Tsuji W, Kivitz A, Peng J, Arnold GE, Boedigheimer MJ, Chiu K, Green CL, Kaliyaperumal A, Wang C, Ferbas J, Chung JB. Inducible T-cell co-stimulator ligand (ICOSL) blockade leads to selective inhibition of anti-KLH IgG responses in subjects with systemic lupus erythematosus. Lupus Sci Med. 2016 Apr 8;3(1):e000146. doi: 10.1136/lupus-2016-000146. eCollection 2016.
- Welcher AA, Boedigheimer M, Kivitz AJ, Amoura Z, Buyon J, Rudinskaya A, Latinis K, Chiu K, Oliner KS, Damore MA, Arnold GE, Sohn W, Chirmule N, Goyal L, Banfield C, Chung JB. Blockade of interferon-gamma normalizes interferon-regulated gene expression and serum CXCL10 levels in patients with systemic lupus erythematosus. Arthritis Rheumatol. 2015 Oct;67(10):2713-22. doi: 10.1002/art.39248.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2008
Primary Completion (ACTUAL)
May 1, 2012
Study Completion (ACTUAL)
May 1, 2012
Study Registration Dates
First Submitted
October 16, 2008
First Submitted That Met QC Criteria
October 16, 2008
First Posted (ESTIMATE)
October 17, 2008
Study Record Updates
Last Update Posted (ESTIMATE)
April 9, 2013
Last Update Submitted That Met QC Criteria
April 5, 2013
Last Verified
April 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20060169
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Systemic Lupus Erythematosus
-
SanofiCompletedCutaneous Lupus Erythematosus-Systemic Lupus ErythematosusJapan
-
Kyowa Kirin Co., Ltd.RecruitingHealthy Volunteers | Systemic Lupus Erythematosus (SLE) | Cutaneous Lupus Erythematosus (CLE)Japan
-
Second Xiangya Hospital of Central South UniversityNational Natural Science Foundation of China; Hunan Provincial Natural Science... and other collaboratorsActive, not recruitingCutaneous Lupus Erythematosus | Systemic Lupus Erythematosus RashChina
-
University Hospital, BrestRecruitingSystemic Lupus Erythematosus (SLE)France
-
Beijing InnoCare Pharma Tech Co., Ltd.RecruitingSystemic Lupus Erythematosus, SLEChina
-
TJ Biopharma Co., Ltd.TerminatedSystemic Lupus Erythematosus (SLE)China
-
AstraZenecaActive, not recruitingActive Systemic Lupus ErythematosusThailand, Korea, Republic of, Philippines, China, Taiwan, Hong Kong
-
Novartis PharmaceuticalsActive, not recruitingSystemic Lupus Erythematosus (SLE)Hungary, Spain, Germany, Israel, Thailand, France, Russian Federation, China, Japan, Taiwan, Korea, Republic of, Poland, Australia, Argentina, Czechia
-
AstraZenecaPRA Health SciencesCompletedActive Systemic Lupus ErythematosusUnited States, France, Germany, Spain, Belgium, Russian Federation, Japan, Korea, Republic of, Argentina, Bulgaria, South Africa, Mexico, Canada, Brazil, Lithuania
-
Novartis PharmaceuticalsNot yet recruitingSystemic Lupus Erythematosus, SLE
Clinical Trials on AMG 557
-
AmgenTerminatedCutaneous Lupus | LupusUnited States, Australia, Canada
-
AmgenCompletedSystemic Lupus ErythematosusUnited States, United Kingdom
-
MedImmune LLCAmgenCompletedPrimary Sjögren's SyndromeUnited States, Sweden, France, United Kingdom
-
AmgenCompletedLupus Arthritis, Systemic Lupus ErythematosusUnited States, Taiwan, Germany, Denmark, Australia, United Kingdom, Malaysia, France
-
AmgenTerminated
-
MedImmune LLCTerminatedRSV InfectionUnited Kingdom
-
MedImmune LLCCompleted
-
AmgenCompletedAdvanced Solid TumorsBelgium, Canada, Australia, United States, Spain, Poland, France, Germany, Japan, United Kingdom
-
AmgenTerminatedRelapsed/Refractory Acute Myeloid Leukemia (AML)United States, Korea, Republic of, Australia, Japan, Germany, Canada